- Subject index
With escalating healthcare costs, changes to the regulatory control on pharmaceutical industries and the inevitable adjustments made in policies and investment in healthcare there is enormous interest in the commercial as well as the scientific aspects of today's healthcare industry.
The SAGE Handbook of Healthcare provides an authoritative analysis of the current (and anticipated) developments in the global healthcare industries. Providing a unique perspective that interfaces between the science and business aspects, it combines information on the latest scientific developments with applied, commercial business data from the global marketplace.
The Handbook focuses on the aspects of paramount importance in the healthcare sector: Pharmacoeconomics; Pharmacogenomics; Therapeutics; Diagnostics
Areas covered include: The role of nanotechnology, genomics and cell therapy in medicine; Diagnostics; Biomarkers and technological advances; Case studies in oncology ...
Chapter 7: Pharmaceutical Pricing and Reimbursement in Canada
Pharmaceutical Pricing and Reimbursement in Canada
Canada is the world's eighth largest pharmaceutical market (after the United States, Japan, Germany, France, the United Kingdom, Italy, and Spain). In 2004, according to IMS Health, pharmaceutical sales in Canada totaled US $10 billion (at ex-manufacturer prices), equivalent to 2.9% of total sales in major world markets. Canada's market share has been rising steadily, reflecting sales growth that has outpaced that of other markets. In 2004, Canada's pharmaceutical sales grew 9% (in local currency terms), while sales grew 8% in the United States, 7% in the United Kingdom and Spain, 5% in France, 3% in Italy, and 1% in Germany. The Canadian Institute for Health Information (CIHI) estimates that the total expenditure for ...